Precision Biosciences (DTIL) Assets Average (2019 - 2026)

Precision Biosciences (DTIL) has 8 years of Assets Average data on file, last reported at $149.2 million in Q1 2026.

• On a quarterly basis, Assets Average rose 14.38% year-over-year to $149.2 million in Q1 2026; TTM through Mar 2026 was $149.2 million, a 14.38% increase from a year earlier, with the FY2025 full-year figure at $145.4 million, down 1.81% from the prior year.
• Assets Average for Q1 2026 stood at $149.2 million, up from $124.0 million in the prior quarter.
• Over the last five years, Assets Average for DTIL reached as high as $284.4 million in Q3 2022 and fell as low as $101.2 million in Q3 2025.
• Historically, Assets Average has averaged $176.3 million across 5 years, with a median of $172.3 million in 2024.
• Across the five-year window, Assets Average increased 24.4% in 2022 and slumped 39.17% in 2023, its largest moves.
• Year by year, Assets Average stood at $255.0 million in 2022, then slumped by 36.43% to $162.1 million in 2023, then dropped by 10.64% to $144.8 million in 2024, then fell by 14.4% to $124.0 million in 2025, then climbed by 20.32% to $149.2 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $149.2 million in Q1 2026, $124.0 million in Q4 2025, and $101.2 million in Q3 2025.